FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Owens Julia C. 2. Issuer Name and Ticker or Trading Symbol Millendo Therapeutics, Inc. [ MLND ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Executive Chair
(Last)         (First)         (Middle)
C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100
3. Date of Earliest Transaction (MM/DD/YYYY)
3/17/2021
(Street)
ANN ARBOR, MI 48104
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $2.29  3/17/2021    A     24000       (1) 3/16/2031  Common Stock  24000.0  $0  24000  D   

Explanation of Responses:
(1)  One-third (1/3) of the shares subject to this option shall vest on February 1, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Owens Julia C.
C/O MILLENDO THERAPEUTICS, INC.
110 MILLER AVENUE, SUITE 100
ANN ARBOR, MI 48104
X
Executive Chair

Signatures
/s/ Jason Minio, Attorney-in-Fact 3/19/2021
**Signature of Reporting Person Date